Editas Medicine, Inc. (EDIT) JPMorgan 40th Annual Healthcare Conference (Transcript)Seeking Alpha • 01/12/22
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/10/22
Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price RecentlySeeking Alpha • 12/28/21
Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta ThalassemiaGlobeNewsWire • 12/20/21
Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual MeetingGlobeNewsWire • 12/12/21
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Editas (EDIT)Zacks Investment Research • 12/07/21
Editas (EDIT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 12/07/21
Here's Why Editas (EDIT) is Poised for a Turnaround After Losing 20.6% in 4 WeeksZacks Investment Research • 12/03/21
Editas Medicine, Inc.'s (EDIT) Management Presents at 4th Annual Evercore ISI HealthCONx Conference (Transcript)Seeking Alpha • 12/02/21
Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual MeetingGlobeNewsWire • 11/12/21
Editas Medicine, Inc. (EDIT) CEO James Mullen on Q3 2021 results - Earnings Call TranscriptSeeking Alpha • 11/08/21